• 25.09.2019 – 17:23

  OrbusNeich

  OrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent

  Hong Kong (ots/PRNewswire) - OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] to combine the proprietary endothelial progenitor cell [EPC] capture technology with an ...

  more

• 22.08.2019 – 09:00

  Daiichi Sankyo

  Daiichi Sankyo Announces the Presentation of New Data on LIXIANA® (edoxaban) to be Presented at ESC Congress 2019

  Munich (ots/PRNewswire) - - Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful ...

  more

• 19.03.2019 – 10:30

  Daiichi Sankyo Europe GmbH

  Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures

  Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...

  more